Distinguished in VIPoma

Martyn E. Caplin

Pond Street, 
London, ENG, GB 
Clinical Trials:Currently Recruiting for 1 Trial
Distinguished in VIPoma
Pond Street, 
London, ENG, GB 
OverviewLocationsClinical Research

Overview

Martyn Caplin practices in London, United Kingdom. Mr. Caplin is rated as a Distinguished expert by MediFind in the treatment of VIPoma. His top areas of expertise are Neuroendocrine Tumor, Pancreatic Islet Cell Tumor, Carcinoid Syndrome, Pancreaticoduodenectomy, and Hepato-Pancreato-Biliary Surgery.

His clinical research consists of co-authoring 171 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of VIPoma.

Gender
Male

Locations

Pond Street, London, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access
SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access
Enrollment Status: Recruiting
Publish Date: May 01, 2025
Intervention Type: Genetic
A Phase III Multi-center, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET
A Phase III Multi-center, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET
Enrollment Status: Active_not_recruiting
Publish Date: August 06, 2025
Intervention Type: Drug
Study Drugs: Lutathera, Octreotide
Study Phase: Phase 3
A Phase 3, Prospective, Randomized, Double-blind, Multi-center Study of the Efficacy and Safety of Lanreotide Autogel®/Depot 120 mg Plus BSC vs. Placebo Plus BSC for Tumour Control in Subjects With Well Differentiated, Metastatic and/or Unresectable, Typical or Atypical, Lung Neuroendocrine Tumours
A Phase 3, Prospective, Randomized, Double-blind, Multi-center Study of the Efficacy and Safety of Lanreotide Autogel®/Depot 120 mg Plus BSC vs. Placebo Plus BSC for Tumour Control in Subjects With Well Differentiated, Metastatic and/or Unresectable, Typical or Atypical, Lung Neuroendocrine Tumours
Enrollment Status: Terminated
Publish Date: July 06, 2022
Intervention Type: Drug
Study Phase: Phase 3
View 2 Less Clinical Trial

171 Total Publications

The indolent nature of type 1 gastric neuroendocrine tumors under 1 cm.
The indolent nature of type 1 gastric neuroendocrine tumors under 1 cm.
Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
Published: July 05, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Caplin's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
View All 25 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile